SELECT Trial Topline Results: Semaglutide Reduces CV MACE in Overweight Patients
Novo Nordisk released SELECT trial topline results showing once-weekly semaglutide at 2.4 mg reduced three-component MACE by 20% compared to placebo in individuals with overweight or obesity and established cardiovascula
The SELECT trial investigated the safety and efficacy of semaglutide in reducing cardiovascular outcomes among patients with overweight or obesity who have established cardiovascular disease but do not have diabetes. This research is significant for metabolic and clinical laboratories as it provides data on long-term treatment effects in a high-risk population previously underrepresented in cardiovascular trials.
The study utilized once-weekly subcutaneous administration of 2.4 mg semaglutide over a five-year duration, comparing outcomes against placebo. Researchers monitored the composite endpoint comprising cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke to assess treatment impact on major adverse cardiovascular events.